PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill aims to keep aggressive lymphoma at bay after initial treatment
Disease control Not yet recruitingThis study tests whether taking duvelisib pills can help prevent cancer from returning in patients with peripheral T-cell lymphoma who have achieved remission after initial chemotherapy. The trial is for patients who have responded well to first treatment but cannot or choose not…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New hope for Tough-to-Treat blood cancer? early trial tests drug combo
Disease control Not yet recruitingThis early-stage trial aims to find a safe and effective dose of a drug called ruxolitinib when given alongside standard chemotherapy (CHOP) for adults newly diagnosed with a rare type of T-cell lymphoma. The main goal is to see if the combination is safe and tolerable. If patien…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC